BG106106A - Приложение на биоразграждащи се микросфери освобождаващи противораково средство за лечение на глиобластом - Google Patents

Приложение на биоразграждащи се микросфери освобождаващи противораково средство за лечение на глиобластом

Info

Publication number
BG106106A
BG106106A BG106106A BG10610601A BG106106A BG 106106 A BG106106 A BG 106106A BG 106106 A BG106106 A BG 106106A BG 10610601 A BG10610601 A BG 10610601A BG 106106 A BG106106 A BG 106106A
Authority
BG
Bulgaria
Prior art keywords
microspheres
biodegradable
release
anticancer agent
biodegradable microspheres
Prior art date
Application number
BG106106A
Other languages
English (en)
Other versions
BG64936B1 (bg
Inventor
Nathalie Faisant
Jean-Pierre Benoit
Philippe Menei
Original Assignee
Laboratoires Des Produits Ethiques Ethypharm S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Des Produits Ethiques Ethypharm S.A. filed Critical Laboratoires Des Produits Ethiques Ethypharm S.A.
Publication of BG106106A publication Critical patent/BG106106A/bg
Publication of BG64936B1 publication Critical patent/BG64936B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до приложението на биоразграждащи се микросфери, освобождаващи лъчесенсибилизиращо противораково средство, което може да се прилага едновременно, отделно от или разпределено във времето с лъчетерапия за лечение на глиобластом. С прилагането му се удължава времето на преживяване на пациента поне с 90 седмици, като се поддържа терапевтично ефективна концентрация в паренхимното пространство. Микросферите съдържат 5-флуороурацил, покрит с поли(d,l-млечна когликолова киселина). Те се имплантират в стените на оперативното място след резекция на тумора чрез вътретъканна инжекция. Лъчелечението, насочено към туморната маса, е дозирано при 60 Gy за около 6 седмици. Изобретението се отнася и до метод за производство на биоразграждащите се микросфери чрез емулсификация-екстракция и до суспензия, която съдържа посочените микросфери.
BG106106A 1999-05-17 2001-11-13 Приложение на биоразграждащи се микросфери, освобождаващи противораково средство за лечение на глиобластом BG64936B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
PCT/FR2000/001315 WO2000069413A1 (fr) 1999-05-17 2000-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome

Publications (2)

Publication Number Publication Date
BG106106A true BG106106A (bg) 2002-05-31
BG64936B1 BG64936B1 (bg) 2006-10-31

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106106A BG64936B1 (bg) 1999-05-17 2001-11-13 Приложение на биоразграждащи се микросфери, освобождаващи противораково средство за лечение на глиобластом

Country Status (30)

Country Link
US (2) US6803052B2 (bg)
EP (2) EP1053746B1 (bg)
JP (1) JP5230045B2 (bg)
KR (1) KR100649948B1 (bg)
CN (1) CN1210020C (bg)
AR (1) AR024008A1 (bg)
AT (1) ATE228353T1 (bg)
AU (1) AU775320B2 (bg)
BG (1) BG64936B1 (bg)
BR (1) BR0010648A (bg)
CA (1) CA2388656C (bg)
CZ (1) CZ20014137A3 (bg)
DE (1) DE60000842T2 (bg)
DK (1) DK1053746T3 (bg)
EA (1) EA004943B1 (bg)
ES (1) ES2185544T3 (bg)
FR (1) FR2793684B1 (bg)
HK (1) HK1047044B (bg)
HU (1) HUP0201224A3 (bg)
IL (2) IL146467A0 (bg)
MX (1) MXPA01011919A (bg)
NO (1) NO331686B1 (bg)
NZ (1) NZ515515A (bg)
PL (1) PL201614B1 (bg)
PT (1) PT1053746E (bg)
SI (1) SI1053746T1 (bg)
SK (1) SK16342001A3 (bg)
TW (1) TWI229608B (bg)
WO (1) WO2000069413A1 (bg)
ZA (1) ZA200109415B (bg)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20022730U1 (de) 1999-08-05 2002-11-21 MAP Medizin-Technologie GmbH, 82152 Planegg Vorrichtung zur Zufuhr eines Atemgases, Befeuchtungsvorrichtung, Atemgasschlauch und Anschlussvorrichtung hierfür
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
WO2003007782A2 (en) 2001-06-29 2003-01-30 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
NZ596207A (en) 2003-06-20 2013-05-31 Resmed Ltd Blower with one of lid and chassis made of metal and plastic composite
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
EP1732594A4 (en) * 2004-03-18 2007-10-17 St Lukes Hospital METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE
EP1763321A4 (en) 2004-04-16 2010-02-17 Critical Care Innovations Inc SYSTEMS AND METHOD FOR ENHANCING ABLATION OF IMAGE-GUIDED FABRIC
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
EP3085361A1 (en) 2004-09-07 2016-10-26 Biocompatibles UK Limited Compositions comprising camptothecins in microspheres
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
SG11201403062YA (en) 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
EP3373907A4 (en) * 2015-11-11 2019-12-18 Qrono, Inc. EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
DE69727491T2 (de) * 1996-10-16 2004-12-02 Regeneron Pharmaceuticals, Inc. Verfahren zur verabreichung von wachstumsfaktoren
EP0911334B1 (en) * 1997-03-31 2008-05-21 Toray Industries, Inc. Quinolinomorphinane derivatives and medicinal use thereof
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
ZA200109415B (en) 2003-01-29
DE60000842T2 (de) 2003-08-28
AU775320B2 (en) 2004-07-29
SI1053746T1 (en) 2003-04-30
EP1053746B1 (fr) 2002-11-27
EA200101206A1 (ru) 2002-04-25
HK1047044B (zh) 2005-12-23
PL201614B1 (pl) 2009-04-30
CN1210020C (zh) 2005-07-13
KR20020000178A (ko) 2002-01-04
HK1047044A1 (en) 2003-02-07
NO20015501L (no) 2002-01-09
NZ515515A (en) 2004-02-27
ES2185544T3 (es) 2003-05-01
WO2000069413A1 (fr) 2000-11-23
ATE228353T1 (de) 2002-12-15
KR100649948B1 (ko) 2006-11-24
EA004943B1 (ru) 2004-10-28
AU4764100A (en) 2000-12-05
CA2388656A1 (fr) 2000-11-23
HUP0201224A2 (hu) 2002-11-28
US7041241B2 (en) 2006-05-09
US20030175356A1 (en) 2003-09-18
BR0010648A (pt) 2002-02-19
CN1356892A (zh) 2002-07-03
NO20015501D0 (no) 2001-11-09
FR2793684B1 (fr) 2001-08-10
CA2388656C (fr) 2011-04-26
HUP0201224A3 (en) 2004-05-28
FR2793684A1 (fr) 2000-11-24
NO331686B1 (no) 2012-02-20
DE60000842D1 (de) 2003-01-09
TWI229608B (en) 2005-03-21
AR024008A1 (es) 2002-09-04
BG64936B1 (bg) 2006-10-31
PT1053746E (pt) 2003-04-30
CZ20014137A3 (cs) 2002-06-12
EP1228755A1 (fr) 2002-08-07
IL146467A0 (en) 2002-07-25
IL146467A (en) 2006-06-11
SK16342001A3 (sk) 2002-08-06
JP5230045B2 (ja) 2013-07-10
JP2002544219A (ja) 2002-12-24
EP1053746A1 (fr) 2000-11-22
US6803052B2 (en) 2004-10-12
US20020051749A1 (en) 2002-05-02
MXPA01011919A (es) 2002-05-06
DK1053746T3 (da) 2003-03-31
PL352372A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
BG106106A (bg) Приложение на биоразграждащи се микросфери освобождаващи противораково средство за лечение на глиобластом
EP1713453A4 (en) IMPLANTABLE DRUG DELIVERY SYSTEM COMPRISING FILAMENTS OR THREADS
Green Antitumor effects of bisphosphonates
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
IL158474A0 (en) Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
IL144597A0 (en) Hydrogel particle formulations
MXPA03005394A (es) Composiciones que contienen complejos de inclusion.
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
NO20033144L (no) Modul¶re transfeksjonssystemer
AU4258101A (en) Combination therapies with vascular damaging activity
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
WO2001074296A3 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
FR2668367B1 (fr) Medicament implantable a effet prolonge.
BR0102314A (pt) Implante farmacêutico para promoção de crescimento
RU2003115986A (ru) Способ лечения сенсоневральной тугоухости